

Integrated Filing (Finance) Ind AS

BAJAJ HEALTHCARE LIMITED

General Information

Scrip code*	539872
NSE Symbol*	BAJAJHCARE
MSEI Symbol*	NOTLISTED
ISIN*	INE411U01027
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	28-07-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-07-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date of board meeting	28-07-2025
Start time of board meeting	16:40:00
End date of board meeting	28-07-2025
End time of board meeting	17:18:00
Whether cash flow statement is applicable on company	

Type of cash flow statement			
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable		
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	false		
No. of times funds raised during the quarter			
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	<table border="1"> <tr> <td>false</td> <td>Textual Information(1)</td> </tr> </table>	false	Textual Information(1)
false	Textual Information(1)		

Text Block

Textual Information(1)	During the quarter ended 30 June 2025, there has been no default of any loan or debt securities.
---------------------------	--

Financial Results - Ind-AS

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-06-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	14,883.63	14,883.63
	Other income	87.77	87.77
	Total income	14,971.40	14,971.40
2	Expenses		
(a)	Cost of materials consumed	6,988.49	6,988.49
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,070.31	1,070.31
(d)	Employee benefit expense	1,435.62	1,435.62
(e)	Finance costs	522.57	522.57
(f)	Depreciation, depletion and amortisation expense	563.65	563.65
(g)	Other Expenses		
1	Brokerage & Commission	101.93	101.93
2	Consumption of Stores Spares and Maintainence	639.62	639.62
3	Freight Forwarding & Transport	265.55	265.55
4	Legal & Professional Expenses	216.09	216.09
5	Power and Fuel	567.50	567.50
6	Processing & Labour Charges	405.65	405.65

7	Travelling & Conveyance Expenses	116.34	116.34
8			
	Total other expenses	2,938.25	2,938.25
	Total expenses	13,518.89	13,518.89
	Total profit before exceptional items and tax	1,452.51	1,452.51
4	Exceptional items	0.00	0.00
5	Total profit before tax	1,452.51	1,452.51
6	Tax expense		
7	Current tax	0.00	0.00
8	Deferred tax	235.14	235.14
9	Total tax expenses	235.14	235.14
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	Net Profit Loss for the period from continuing operations	1,217.37	1,217.37
12	Profit (loss) from discontinued operations before tax	(45.43)	(45.43)
13	Tax expense of discontinued operations	(11.43)	(11.43)
14	Net profit (loss) from discontinued operation after tax	(34.00)	(34.00)
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	1,183.37	1,183.37
17	Other comprehensive income net of taxes	18.71	18.71
18	Total Comprehensive Income for the period	1,202.08	1,202.08
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	1,579.16	1,579.16
	Face value of equity share capital	5.00	5.00

22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	3.85	3.85
	Diluted earnings (loss) per share from continuing operations	3.75	3.75
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	(0.11)	-0.11
	Diluted earnings (loss) per share from discontinued operations	(0.11)	-0.11
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	3.74	3.74
	Diluted earnings (loss) per share from continuing and discontinued operations	3.64	3.64
24	Debt equity ratio	0.48	0.4800
25	Debt service coverage ratio	0.55	0.5500
26	Interest service coverage ratio	3.78	3.7800
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	Note
	<p>1 The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 28 July 2025 These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion</p> <p>2 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year</p> <p>3 The above unaudited financial results for the quarter ended 30 June 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing obligations and disclosure requirements Regulations 2015 as amended</p> <p>4 The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment ie Pharmaceuticals</p> <p>5 In the previous financial year ended 31 March 2024 the Board of Directors had approved to sale disposal of undertaking unit s on going concern basis situated at plot no N92 L9 3 T 30 MIDC Tarapur Taluka Boisar District Palghar Maharashtra and vacant industrial land situated at plot no D2 CH 42 and D2 CH 43 Dahej industrial area GIDC Bharuch Gujarat which were acquired under SARFAESI ACT 2022 from Saraswat Bank and plot no E62 and E63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra The approval of shareholders was obtained vide postal ballot The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations The results of the operation of these units have been presented separately on the statement</p>

of profit and loss as discontinued operations. Considering these assets are held for sale the assets have been recorded at their fair value on the date these assets has been classified as held for sale Out of these one unit situated at plot number N 92 was sold during the Quarter ended 31 March 2024 The total value of assets classified as held for sale represents lower of carrying value or fair value

The financial information from discontinued operations

Particulars	Quarter Ended	Year ended	30 June 2025	31 March 2025	30 June 2024	31 March 2025
Total Income A	2.10	-37.81	6.13	58.07		
Total Expenses B	47.53	50.22	118.10	459.18		
Loss before Tax from Discontinued Operations C = A Less B	-45.43	-88.03	-111.97	-401.11		
Tax Expense or Credit from Discontinued Operations D	-11.43	-46.51	-22.53	-57.78		
Loss after Tax from Discontinued Operations E = C Less D	-34.00	-41.52	-89.44	-343.33		

6 The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra Ordinary General Meeting EGM held on Wednesday 07 August 2024 through Video Conferencing VC Other Audio Visual Means OAVM approved the issue of 4044852 Equity Shares at Rs 338 per share including premium at Rs 333 per share to Person s belonging to non promoter category on preferential basis and the issue of convertible equity warrants 2079409 at Rs 338 per warrant including premium at Rs 333 per share to Person s belonging to promoter category as well as non promoter category on preferential basis The object of the issue is to repayment of term loan investment in capital expenditure and general corporate purpose The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd On 19 September 2024 post approval from Board the Company has allotted 3984852 number of equity shares and 2079409 convertible warrants and has also filed the relevant form with Registrar of Companies The uncalled amount of share warrants as at 30 June 2025 is Rs 5271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024.

7 The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities

Particulars Rs in Lakhs

Repayment and prepayment of secured or unsecured loans from bank or NBFC 15,000.00

General corporate purpose 225.90

Total 15,225.90

8 In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited in Liquidation Genrx on a going concern basis Genrx is an existing company incorporated under the provisions of the Companies Act 1956 The acquisition was made for a total consideration of Rs 1085 lakhs

Subsequently on 3 June 2025 the Company filed an application with the Honourable National Company Law Tribunal NCLT Mumbai seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110

Consolidated Financial Statements is not established

9 Previous year period figures have been regrouped to make them comparable with the current year period figures which are not material

Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025	01-04-2025
Date of end of reporting period	30-06-2025	30-06-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]		
1 Amount of items that will not be reclassified to profit and loss		
1 Items that will not be reclassified to profit or loss	25.00	25.00
Total Amount of items that will not be reclassified to profit and loss	25.00	25.00
2 Income tax relating to items that will not be reclassified to profit or loss	6.29	6.29
3 Amount of items that will be reclassified to profit and loss		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	18.71	18.71